No Data
No Data
RSV Vaccine Market to Decline 64% on CDC Decision: Report
GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests
GSK Wins EU Backing for RSV Vaccine for Those Aged 50 – 59
GlaxoSmithKline Sell Rating Justified by Arexvy Underperformance and Reduced Revenue Projections
GSK Says Health Canada Approves Jemperli as Endometrial Cancer Treatment
GlaxoSmithKline (GSK) Receives a Buy From Jefferies
No Data